open access
Differential diagnosis of inflammatory myopathies, Becker muscular dystrophy (BMD) in a 10-year-old boy
Affiliations- Oddział Kliniczny Dzieci Starszych z pododdziałami Neurologii i Reumatologii, ul. Strzelecka 2, 31-503 Kraków, Poland
open access
Abstract
The article presents the case of a 10-year-old boy referred for rheumatic diagnosis with suspected inflammation of the muscles without the presence of skin lesions in which Becker muscular dystrophy (BMD) was diagnosed. In cases of isolated myopathy without skin lesions, it is necessary to exclude the neurogenic origin of muscle damage, muscular dystrophies and myasthenic disorders, additionally, viral, bacterial, parasitic infectious myopathy should be considered as a result of hormonal disturbances, drug poisoning and metabolic and electrolyte disorders. Becker muscular dystrophy is a genetically conditioned disease that causes progressive and irreversible muscular atrophy, and is inherited in a recessive manner in gender-related intercourse. The incidence is around 1.5–6/100,000 births of boys. Becker dystrophy is a milder form of the Duchenne dystrophy type (DMD). The first symptoms occur at the age of 6–12 years. They include duck feet, problems with running and climbing stairs. The disease is progressive, initially affects the skeletal muscles, then also the myocardium leading to cardiomyopathy. Loss of ability to move independently occurs later, only after the age of 16. The average survival period is 45 years.
Forum Reumatol. 2019, tom 5, nr 1: 43–46
Abstract
The article presents the case of a 10-year-old boy referred for rheumatic diagnosis with suspected inflammation of the muscles without the presence of skin lesions in which Becker muscular dystrophy (BMD) was diagnosed. In cases of isolated myopathy without skin lesions, it is necessary to exclude the neurogenic origin of muscle damage, muscular dystrophies and myasthenic disorders, additionally, viral, bacterial, parasitic infectious myopathy should be considered as a result of hormonal disturbances, drug poisoning and metabolic and electrolyte disorders. Becker muscular dystrophy is a genetically conditioned disease that causes progressive and irreversible muscular atrophy, and is inherited in a recessive manner in gender-related intercourse. The incidence is around 1.5–6/100,000 births of boys. Becker dystrophy is a milder form of the Duchenne dystrophy type (DMD). The first symptoms occur at the age of 6–12 years. They include duck feet, problems with running and climbing stairs. The disease is progressive, initially affects the skeletal muscles, then also the myocardium leading to cardiomyopathy. Loss of ability to move independently occurs later, only after the age of 16. The average survival period is 45 years.
Forum Reumatol. 2019, tom 5, nr 1: 43–46
Keywords
myositis; muscular dystrophy; molecular diagnostics
About this articleTitle
Differential diagnosis of inflammatory myopathies, Becker muscular dystrophy (BMD) in a 10-year-old boy
Journal
Issue
Article type
Case report
Pages
43-46
Published online
2019-04-04
Page views
763
Article views/downloads
1822
DOI
Bibliographic record
Forum Reumatol 2019;5(1):43-46.
Keywords
myositis
muscular dystrophy
molecular diagnostics
Authors
Dorota Turowska-Heydel
Zbigniew Żuber
References (8)- Kissel JT, Mendell JR. Muscular dystrophy: historical overview and classification in the genetic era. Semin Neurol. 1999; 19(1): 5–7.
- Hausmanowi-Petrusewicz I. Choroby nerwowo-mięśniowe. Czelej, Lublin 2005: 167–178.
- Szmidt-Sałkowska E. Dorobek M. Nowe poglądy na patogenezę dystrofii mięśniowych postępujących (DMP) Polski przegląd Neurologiczny. 2006; 2: 117–124.
- Koening M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker Muscular Dystrophy: correlation of severity with type of deletion . Am.J.Hum.Genet. 1989; 45: 498–506.
- Behrman RE, Kliegman RM, Nelson WE, Vaughan VC. Podręcznik pediatrii . PWN, Warszawa 1996.
- Passamano I, Taglia A, Palladino A, et al. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myologica. 2012; XXXI: 121–125.
- Andrews JG, Wahl RA. Duchenne and Becker muscular dystrophy in adolescents: current perspectives. Adolesc Health Med Ther. 2018; 9: 53–63.
- Beenakker EAC, Fock JM, Van Tol MJ, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol. 2005; 62(1): 128–132.
